CRANFORD, N.J., Sept. 8, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company focused on developing and
commercializing critical care drug products, today announced that
its management is scheduled to present at the H.C. Wainwright
22nd Annual Global Investment Conference to be held
virtually on September 14-16,
2020. Leonard Mazur, Chairman of Citius, will present on
Tuesday, September 15, at
11:00 a.m. Eastern Time where he will
deliver a corporate overview of the Company.
In addition he will be providing updates that include the recent
expansion of the Company's intellectual property for Mino-Wrap, a
novel approach to reducing post-operative infections associated
with surgical implants, future plans to potentially treat and
reduce the severity of acute respiratory distress syndrome (ARDS)
associated with COVID-19, and Mino-Lok®, an antibiotic lock
treatment for catheter-related bloodstream infections (CRBSIs), in
collaboration with MDACC.
Webcast: https://wsw.com/webcast/hcw7/ctxr/1629433
Mr. Mazur will conduct virtual one-on-one meetings with
investors during the conference.
About Citius Pharmaceuticals, Inc.
Citius is a
late-stage specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives and cancer care. For more information,
please visit www.citiuspharma.com.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "should," and
"may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results
to differ materially from those currently anticipated are: the risk
of successfully negotiating within the option period a license
agreement with Novellus; risks associated with conducting clinical
trials and drug development; market and other conditions; our
ability to attract, integrate, and retain key personnel; our need
for substantial additional funds;, Inc. for our planned Novecite
therapy for ARDS; the estimated markets for our product candidates
and the acceptance thereof by any market; risks related to our
growth strategy; risks relating to the results of research and
development activities; uncertainties relating to preclinical and
clinical testing; the early stage of products under development;
our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; our ability to identify,
acquire, close and integrate product candidates and companies
successfully and on a timely basis; our dependence on third-party
suppliers; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contact:
Andrew
Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-hc-wainwright-virtual-22nd-annual-global-investment-conference-301124698.html
SOURCE Citius Pharmaceuticals, Inc.